Brookline Capital Management Forecasts MNPR Q1 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Research analysts at Brookline Capital Management issued their Q1 2026 earnings per share (EPS) estimates for Monopar Therapeutics in a report issued on Thursday, September 25th. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings of ($0.81) per share for the quarter. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics’ Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.82) EPS and Q4 2026 earnings at ($0.83) EPS.

Several other research firms have also issued reports on MNPR. BTIG Research lifted their price objective on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, September 25th. HC Wainwright set a $105.00 target price on Monopar Therapeutics and gave the company a “buy” rating in a report on Monday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, September 24th. Piper Sandler set a $95.00 price objective on Monopar Therapeutics and gave the company an “overweight” rating in a report on Thursday, September 25th. Finally, Oppenheimer began coverage on Monopar Therapeutics in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $77.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Monopar Therapeutics has an average rating of “Buy” and an average price target of $86.22.

Monopar Therapeutics Stock Up 7.6%

NASDAQ MNPR opened at $81.67 on Monday. The stock has a market capitalization of $503.90 million, a PE ratio of -24.53 and a beta of 1.20. Monopar Therapeutics has a 12-month low of $4.50 and a 12-month high of $81.89. The company has a 50 day moving average price of $45.78 and a two-hundred day moving average price of $40.11.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MNPR. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Monopar Therapeutics during the second quarter valued at about $34,000. AlphaQuest LLC bought a new position in Monopar Therapeutics during the first quarter valued at about $44,000. JPMorgan Chase & Co. raised its holdings in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Monopar Therapeutics in the 2nd quarter valued at approximately $80,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Monopar Therapeutics in the 2nd quarter worth approximately $104,000. Institutional investors own 1.83% of the company’s stock.

Insiders Place Their Bets

In other news, Director Christopher M. Starr sold 16,800 shares of the firm’s stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the sale, the director owned 5,173 shares in the company, valued at approximately $206,920. This trade represents a 76.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the business’s stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the transaction, the director directly owned 11,486 shares in the company, valued at $459,440. This trade represents a 43.67% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 592,733 shares of company stock worth $36,700,227. Corporate insiders own 20.50% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.